

Kemin licenses another poultry vaccine from Pacific GeneTech

16 October 2020 – Animal Health | Headline Analysis
Research & Development, Food Animals



Joseph Harvey
Editor

Kemin Industries and Pacific GeneTech (PGT) have increased their commercial partnership to include the latter's *Eimeria* vaccine for poultry.

The two firms have an existing pact for PGT's *Salmonella* vaccine for poultry. The latest exclusive partnership is for PGT's TMH001 inactivated oral vaccine, which Kemin claims will be the only product of its kind when commercialized.

The vaccine was created using PGT's proprietary Aegis platform – technology that was originally developed by the University of Arkansas' Poultry Health Laboratory in collaboration with other US universities and the USDA. The Aegis vaccine platform combines cross-protective antigens and immunopotentiators in vectors, for broad spectrum protection against multiple strains and species of infectious diseases.

The TMH001 vaccine will be commercialized through Kemin Biologics, which is currently building a portfolio of vaccines with partners to sell globally.

Under the terms of the partnership, Kemin will further develop TMH001 and register it in the US. A spokesperson for Kemin told IHS Markit Animal Health development work for the vaccine is underway and "progressing as planned", although there is no launch date scheduled as of yet. The company is also aiming to take TMH001 to Europe, Asia, the Middle East, Africa and Latin America.

Kemin stated: "In addition to a high safety profile, TMH001 provides demonstrable cross-protection against five economically important species of *Eimeria* with the potential to protect against more species."

While Kemin is a global ingredient manufacturer across several sectors, it branched out into veterinary vaccines when it purchased a stake in Aptimmune Biologics. The deal resulted in the creation of Kemin AptiVax, which will exclusively manufacture and sell Aptimmune's mucosal vaccine technology for swine outside the US. The company also owns Kemin Biologics.

This year, PGT secured the first approval of a poultry vaccine that uses its Hercules adjuvant technology. The firm is also working with US-based EpiVax to develop a vaccine for African swine fever.

Source: IHS Markit, Animal Pharm